Immune Therapy Holdings AB or ITH is a
Swedish
Swedish or ' may refer to:
Anything from or related to Sweden, a country in Northern Europe. Or, specifically:
* Swedish language, a North Germanic language spoken primarily in Sweden and Finland
** Swedish alphabet, the official alphabet used by ...
biotechnology R&D holding company headquartered at the
Karolinska Institutet and
Karolinska University Hospital
The Karolinska University Hospital ( sv, Karolinska universitetssjukhuset) is a teaching hospital affiliated with Karolinska Institutet in Stockholm, Sweden, with two major sites in the municipalities of Solna and Huddinge. The hospital network is ...
in
Stockholm
Stockholm () is the Capital city, capital and List of urban areas in Sweden by population, largest city of Sweden as well as the List of urban areas in the Nordic countries, largest urban area in Scandinavia. Approximately 980,000 people liv ...
.
ITH's research is primarily focused on its Tailored Leukapheresis (TLA) treatment for
immune mediated inflammatory diseases (IMIDs).
[ITH Introduction]
December 2012
Tailored Leukapheresis treatment
Tailored Leukapheresis (TLA) treatment is an
apheresis immunotherapy for selective removal of disease-causing pro-inflammatory cells
extracorporeal
An extracorporeal is a medical procedure which is performed outside the body. Extracorporeal devices are the artificial organs that remain outside the body while treating a patient. Extracorporeal devices are useful in hemodialysis and cardiac surg ...
ly, which has
therapeutic application in various IMIDs that are caused and maintained by inflammation.
TLA utilises the natural affinity of
chemokines and
chemokine receptors to selectively attract, bind, and deplete circulating pro-inflammatory cells ''en route'' to the site of inflammation. It is the first, and hitherto novel, apheresis technology with a demonstrated efficacy in targeting and removing selected
leukocytes while leaving all other blood cells unaffected.
The immunotherapy has been evaluated in a Phase I/II
placebo-controlled clinical trial, where all primary and secondary
clinical endpoints were met and the treatment showed an absence of any side effects of clinical significance.
[ClinicalTrials.Gov]
2010
Awards and funding
TLA received the
Dagens Medicin's Athena Prize (Sweden, 2013)
[Dagens Medicin]
2013 and Universal Biotech Innovation Prize (France, 2012).
[Universal Biotech]
2012 During 2014, TLA was selected by the
Swedish Institute
The Swedish Institute ( sv, Svenska institutet, ) is a government agency in Sweden with the responsibility to spread information about Sweden outside the country. It exists to promote Swedish interests, and to organise exchanges with other co ...
for its Innovative Sweden exhibition that highlights
Swedish innovativeness worldwide.
[Swedish Institute]
2014
TLA has received competitive research funding from the following sources:
* 2010:
Swedish Governmental Agency for Innovation Systems (Phase I/II
Clinical Trial on
IBD):
SEK 5 Million.
[ITH VINNOVA Press Release]
2010
* 2012:
European Union Eureka EUROSTARS (Phase I/II Clinical Trial on
ARDS): SEK 5 Million.
[EUROSTARS Project]
2012
* 2013:
Swedish Research Council
The Swedish Research Council ( sv, Vetenskapsrådet) is a Government agency in Sweden established in 2001, with the responsibility to support and develop basic scientific research. Its objective is for Sweden to be a leading nation in scienti ...
(Phase I/II Clinical Trial on
paediatric IBD,
PSC,
alcoholic hepatitis,
RA,
MS and
ALS
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a neurodegenerative disease that results in the progressive loss of motor neurons that control voluntary muscles. ALS is the most com ...
): SEK 5 Million.
[Swedish Medical Research Council]
December 2012
* 2013:
Swedish Governmental Agency for Innovation Systems (Phase II Clinical Trial on
IBD): SEK 5 Million
Target market
The global anti-inflammatory therapeutics market was $57.8 billion in 2010 and is estimated to increase at a
CAGR of 5.8% between 2010 and 2017 to a total value of $85.9 billion.
[PR NewsWire Global Anti-Inflammatory Therapeutics Market]
2011
References
{{Reflist
Research and development in Sweden
Biotechnology
Swedish companies established in 2005
Biotechnology companies established in 2005